EBMC-710GO FOR OBESITY

EBMC-710GO, our lead asset, is an oral MC3R/ MC4R dual agonist in clinical development as a next-generation weight-loss treatment

EBMC-710GO is being evaluated in a Phase 1 clinical trial in people with overweight or obesity

A man and woman embrace and smile outdoors, surrounded by other people in a park setting.

In compelling nonhuman primate studies, EBMC-710GO has shown weight loss comparable to GLP-1 agonists with a healthier, more durable product profile

Kalohexis addresses shortcomings in the standard-of-care in a market with massive unmet need

Overweight and obese
adults in the US
Annual medical
expenditures
of US healthcare
spending

EBMC-710GO is designed to activate both MC3R and MC4R in a balanced manner, dialing up the metabolic thermostat to reduce appetite and increase energy expenditure, potentially leading to durable weight loss. Based on data from animal models of obesity, EBMC-710GO goes beyond appetite suppression to drive healthier weight loss that preserves lean mass and avoid weight rebound following discontinuation. We are evaluating EBMC-710GO in humans as a monotherapy and also in combination with standard-of-care weight-loss regimens, positioning it to complement incretin-based therapies for the treatment of general obesity. In addition, MC3R/MC4R dual agonism may offer a new approach to the treatment of rare genetic, syndromic and acquired hypothalamic forms of obesity.

1

Effective Weight Loss

Achieved 11.7% weight loss in 13 weeks in primate models of diet-induced obesity

2

Minimal Weight Regain

Unlike GLP-1s, 710GO showed minimal rebound weight gain after treatment discontinuation in animal studies

3

Lean Mass Sparing

Preferential reduction in fat mass and retention of lean mass in obese animal models

4

Complementary Mechanism

Potential for combination with incretin-based therapies